Comparison between guttate and plaque psoriasis in terms of serum inflammatory cytokines and antimicrobial peptides

摘要

Psoriasis is a chronic inflammatory skin disease, and immunological disorder plays a crucial role in the pathogenesis of psoriasis. Antimicrobial peptides (AMPs), including cathelicidin (LL-37) and human beta-defensin (HBD)-3, are not only the basis of innate immunity but also a bridge to activate adaptive immunity. In the immune response, several inflammatory cytokines, including tumor necrosis factor-α, interleukin (IL)-6, IL-10, IL-17, IL-22, and IL-23, are involved in the occurrence and development of psoriasis.[1] Guttate psoriasis was known to have a better prognosis than other types of psoriasis with a rapid regression and a longer remission period. However, 33.0% to 68.3% of guttate psoriasis subsequently develops into chronic plaque psoriasis during the follow-up period of at least 1 or 10 years.[2] However, the association of pathogenesis between guttate and plaque psoriasis is not clear, and most studies only focus on inflammatory cytokine changes in plaque psoriasis rather than in guttate psoriasis. This study aimed to compare the levels of serum inflammatory cytokines and AMPs of the variants (plaque vs. guttate) of psoriasis vulgaris, specifically some potential treatment targets, and to reveal the pathogenesis in different clinical manifestations.